Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am so very sad to hear this, he fought so hard for so long. Deepest sympathies to his family.
Thanks for sharing, tctrader38.
Thank you IkeEsq! Much appreciated!!
Thank you Dr Bala!
jon_k84,
muee88 is a patent expert:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163771850
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163771878
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163786336
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163808540
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163810071
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163866880
Great news! Thanks muee88!
Fascinating video (29 sec. - the entire process was recorded in 1 hour and 40 minutes) of a battle between the immune cell soldier and a highly aggressive skin cancer cell .
The immune cell soldier is a so called "cytotoxic T-cell", also known as "CD8+ T-cell" or "killer T-cell". Cytotoxic T-cells are the immune system’s ground troopers, equipped with tools to detect and destroy any abnormal or invading cell.
Jeroen Slaats used the Leica SP8 confocal microscope for recording this battle.
Thank you MI Dendream for the compliment. I thank you for the many contributions! Always very enlightening.
Thank you muee88! Great info!
Thank you hmuney!
Kwok Pang - Chief Operating Officer at Autolomous
32 minutes ago
Help Joel Live Longer!
UPDATE:
For what it's worth. I asked MHRA about the ILAP applications.
My Q:
learningcurve2020,
Thank you. I keep that in mind!
Exciting! Congratulations Dr Bala!
Gilead Sciences, Inc.’s breast cancer drug Trodelvy is to undergo assessment via the UK’s new post-Brexit approval system for novel medicines, the Innovative Licensing and Access Pathway (ILAP).
April 1, 2021
learningcurve2020,
Do you think the CVM clinical trial will ultimately succeed?
I agree, ATLnsider.
Monday, April 26, 2021
Article:
Preparing for Process Improvements: Discussions of the Cell Therapy Industry’s Supply Chain, Automation, and Control Needs.
Mike Scott
Chief Operating Officer at Advent Bioservices.
5h ago:
Thanks. Here is an application of a study in an early phase:
April 20, 2021
Gary, Northwest Biotherapeutics is not on the online exhibitor list as of April 20, 2021. So maybe wait and see what happens!
Nick119, thank you for sharing the pdf for the (or one of) portion of the book that deal with DCvax.
Gary, when the floor plan was first posted (April 16) on this message board I asked Eileen McGill, CEM Senior Manager, Exhibit Operations, about it.
Here is her reply:
biosectinvestor,
I think they created a “synthetic” control data set using external control data available from similar RCTs (Weller 2017, Stupp 2017, Gilbert 2013, Wen 2019), where eligibility criteria and known patient characteristics are reasonably similar, and adjusted using any of a variety of statistical methodologies.
IMO, they will measure comparatively from “randomization”.(as you suggest)
exwannabe,
Correct, all reported from randomization. None from surgery. Randomization in Weller et al. 2017 and Stupp et al. 2017 ( and i assume Gilbert 2013 and Wen 2019) took place 3 – 4 months post surgery. One exception, Gilbert 2014 randomized study subjects at an earlier timepoint then the other studies, and any analysis that would use this study as an external control comparator will be conducted both including and excluding this study.
DEC.11, 2019
Dr. Bosch’s Presentation at GBM Drug Development Summit in Boston: DCVax®-L Phase III Trial, “Where Are We, And How Did We Get Here?”
Doc logic,
I like this recent twitter conversation between Brad Loncar (Biotech investor) and Anthony Davies (Founder & CEO of the only global consulting practice focused exclusively on cell & gene therapy
@darkhorsecagt).
April 9,
Spot on @bradloncar , it's brain surgery and rocket science, and if it were easy it would have been done already. As Brad does with financial analysis, you can't beat getting deeply involved in the technical details, sticking to fundamentals and execution
— Anthony Davies (@ADaviesDHCG) April 9, 2021
Thank you Nick for sharing the message!
Referring to the CRL/Cognate PR, it is noted: “Dark Horse Consulting Group, Inc. is acting as Charles River’s strategic advisor.”
Anthony Davies is Founder and CEO of Dark Horse Consulting Group Inc.
Here is a link to a recent podcast(April 19):https://open.spotify.com/episode/26geOCZ7kKGSbknCV46Mh2
around min.41, Anthony Davies ”macro crystal ball of the field”.
Thank you ATLnsider! Nice job.
Brown Rudnick’s Global Life Sciences Group
What have we done lately?
Flaskworks LLC: Advised on the sale to Northwest Biotherapeutics.
Exhibits
Launching mid-May, Exhibits will remain online until early July. Exhibit access is included with registration. Exhibits will offer attendees the ability to virtually drop a business card, browse each exhibitor's booth, explore the new Clinical Trials and Pharmaceutical Pipelines directories, connect with ASCO representatives, and more. While on the Exhibits site, make sure to tune into an Industry Expert Theater—either live or on-demand— featuring the latest drug development research.
https://dailynews.ascopubs.org/do/10.5555/ADN.21.200502/full/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=ASCO_Daily_News_TrendMD_0#s4